Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

@article{Sevigny2015AducanumabA,
  title={Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study},
  author={Jeff Sevigny and Ping Chiao and Leslie Williams and Tianle Chen and Yan Ling and John O’Gorman and Christoph Hock and Roger M. Nitsch and Alfred W. Sandrock},
  journal={Alzheimer's \& Dementia},
  year={2015},
  volume={11}
}
View on Elsevier
doi.org
35 Citations
Background Citations
9
Results Citations
1

35 Citations

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy

A critically review the growing body of evidence supporting the monitoring of CSF anti-Aβ autoantibody as a promising candidate biomarker for ARIA in clinical trials.

Developing therapeutic vaccines against Alzheimer’s disease

Greater therapeutic efficacy for the next generation of vaccine approaches will likely benefit from specifically targeting the most toxic species of Aβ and tau, ideally simultaneously.

Molecular Imaging in Alzheimer Clinical Trials

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis

Given the clinical therapeutic effects of anti‐Aβ immunotherapies for AD, aducanumab and solanezumab improve the cognitive function, while aducanical and bapineuzumab may increase the risks of ARIA.

Targeting microglia for the treatment of Alzheimer's Disease

The considerations in selecting microglial therapeutic targets from the perspective of drug discovery feasibility are discussed, and the role of microglia in ongoing immunotherapy clinical strategies is considered.

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

This commentary focuses on the prophylactic immunotherapy of Alzheimer's disease using recombinant Aβ B-cell epitope chimeric protein as subunit vaccine targeting amyloid-β, and discusses the efficiency and perspective of this type of recombinant subunit protein vaccine.

Emerging amyloid and tau targeting treatments for Alzheimer’s disease

There is a significant need for further research targeting the disease at an earlier stage and progress in biomarker and imaging technology are improving the outlook, allowing development of effective targeted treatments.

Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.

Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors

The authors focus on the regulatory factors, which mediate AD pathology, and discuss a variety of newly developed drugs and compounds used to inhibit β- secretase and γ-secretase activity, remove oligomeric Aβ and aggregated Aβ that is given responsibility in the amyloid cascade hypothesis.

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

Current “anti‐Alzheimer's” agents currently in clinical trials are summarized based on findings available in the Thomson Reuters «Integrity» database, on the public website www.clinicaltrials.gov, and on database of the website Alzforum.org.